Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients

Journal of Lipid Research

Volumn 40, Issue 4, 1999, Pages 636-647

  Marcoux, Caroline ^a   Tremblay, Michel ^a   Nakajima, Katsuyuki ^b   Davignon, Jean ^a   Cohn, Jeffrey S ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

ApoC III; ApoE; Atherosclerosis; LDL; Triglyceride rich lipoprotein remnants

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; REMNANT LIKE PARTICLE TRIGLYCERIDE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HYPERLIPOPROTEINEMIA TYPE 3; HYPERLIPOPROTEINEMIA TYPE 4; PRIORITY JOURNAL; PROTEIN ISOLATION; THROMBOGENICITY; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; APOLIPOPROTEIN C-III; APOLIPOPROTEINS B; APOLIPOPROTEINS C; APOLIPOPROTEINS E; CHOLESTEROL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; HYPERLIPOPROTEINEMIA TYPE III; HYPERLIPOPROTEINEMIA TYPE IV; LIPOPROTEINS; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; PARTICLE SIZE; TRIGLYCERIDES;

EID: 0032941089     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Gianturco, S. H., and W. A. Bradley. 1991. Triglyceride-rich lipoproteins and their role in atherosclerosis. Curr. Opin. Lipidol. 2: 324-328.
2. Havel, R. 1994. McCollum Award Lecture. 1993: Triglyceride-rich lipoproteins and atherosclerosis-new perspectives. Am. J. Clin. Nutr. 59: 759-795.
3. Hamsten, A. 1993. The hemostatic system and coronary heart disease. Thromb. Res. 70: 1-38.
4. Mjøs, O. D., O., Faergeman, R. L. Hamilton, and R. J. Havel. 1975. Characterization of remnants produced during the metabolism of triglyceride-rich lipoproteins of blood plasma and intestinal lymph in the rat. J. Clin. Invest. 56: 603-615.
5. Havel, R. J. 1997. Triglyceride-rich lipoprotein remnants. In Handbook of Lipoprotein Testing. N. Rifai, G. R. Warnick, and M. H. Dominiczak, editors. AACC Press, Washington, DC. 451-464.
6. Cohn, J. S., and J. Davignon. 1998. Different approaches to the detection and quantification of triglyceride-rich lipoprotein remnants. In Atherosclerosis XI. B. Jacotot, D. Mathe, and J-C. Fruchart, editors. Elsevier Science Singapore. 771-776.
7. Nakajima, K., T. Saito, A, Tamura, M. Suzuki, T. Nakano, M. Adachi, A. Tanaka, N. Tada, H. Nakamura, E. Campos, and R. J. Havel. 1993. Cholesterol in remnant-like lipoproteins in human serum using monoclonal and apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin. Chim. Acta. 223: 53-71.
8. Nakajima, K., M. Okazaki, A. Tanaka, C. R. Pullinger, T. Wang, T. Nakano, M. Adachi, and R. J. Havel. 1996. Separation and determination of remnant-like particles in human serum using monoclonal antibodies to apoB-100 and apo AI. J. Clin. Lig. Assay. 19:177-183.
9. Marcoux, C., M. Tremblay, H. Jacques, L. Krimbou, A. Fredenrich, K. Nakajima, J. Davignon, and J. S. Cohn. 1998. Plasma remnant-like particle lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects. Atherosclerosis. 139: 161-171.
10. McNamara, J. R., P. K. Shah, K. Nakajima, L. A. Cupples, P. W. F. Wilson, J. M. Ordovas and E. J. Schaefer. 1996. Remnant lipoprotein cholesterol and triglyceride reference ranges from the Framingham Heart Study. Clin. Chem. 44: 1224-1232.
11. Ikewaki, K., H. Shige, K. Nakajima, and H. Nakamura. 1995. Postprandial remnant-like particles and coronary artery disease. In Atherosclerosis X, F. P. Woodward, J. Davignon, and A. Sniderman, editors. Elsevier, Amsterdam. 200-202.
12. Shimizu, H., M. Mori, and T. Sato. 1993. An increase of serum remnant-like particles in non-insulin-dependent diabetic patients with microalbuminuria. Clin. Chim. Acta. 221: 191-196.
13. Nakajima, K., T. Saito, A. Tamura, M. Suzuki, T. Nakano, M. Adachi, A. Tanaka, N. Tada, H. Nakamura, and T. Murase. 1994. A new approach for the detection of type III hyperlipoproteinemia by RLP-cholesterol assay. J. Atheroscler. Thromb. 1: 30-36.
14. Devaraj, S., G. Vega, R. Lange, S. M. Grundy, and I. Jialal. 1998. Remnant-like particle cholesterol levels in patients with dysbeta-lipoproteinemia or coronary artery disease. Am. J. Med. 104: 445-450.
15. Sekihara, T., T. Nakano, and K. Nakajima. 1996. High postprandial plasma remnant-like particles-cholesterol in patients with coronary artery diseases on chronic maintenance hemodialysis. Jpn. J. Nephrol. 38: 220-228.
16. Oda, H., N. Yorioka, S. Okushin, Y. Nishida, S. Kushihata, T. Ito, and M. Yamakido. 1997. Remnant-like particles cholesterol may indicate atherogenic risk in patients on chronic hemodialysis. Nephron. 76: 7-14.
17. Tanaka, A., N. Ejiri, Y. Fujinuma, K. Yui, M. Tamura, K. Nakajima, M. Morohoshi, K. Fujisawa, I. Uchimura, and F. Numano. 1995. Remnant-like particles and restenosis of coronary arteries after PTCA. Ann. NY Acad. Sci. 748: 595-598.
18. Nakamura, H., K. Ikewaki, M. Nishiwaki, and H. Shige. 1995. Postprandial hyperlipidemia and coronary artery disease. Ann. NY Acad. Sci. 748: 441-446.
19. McNamara, J. R., P. K. Shah, S. M. Nelson, K. Nakajima, P. W. F. Wilson, and E. J. Schaefer. 1996. Lipoprotein remnant cholesterol and triglyceride values in coronary cases and Framingham controls. Circulation. 94:1-94 (abstract).
20. Tomono, S., S. Kawazu, N. Kato, T. Ono, C. Ishii, Y. Ito, M. Shimizu, M. Shimoyama, T. Nakano, and K. Nakajima. 1994. Uptake of remnant like particles (RLP) in diabetic patients from mouse peritoneal macrophages. J. Atheroscler. Thromb. 1: 98-102.
21. Knōfler, R., T. Nakano, K. Nakajima, Y. Takada, and A. Takada. 1995. Remnant-like lipoproteins stimulate whole blood platelet aggregation in vitro. Thromb. Res. 78: 161-171.
22. Mochizuki, M., T. Y. Takada, T. Urano, N. Nagai, T. Nakano, K. Nakajima, and A. Tanaka, 1996. The in vivo effects of chylomicron remnant and very low density lipoprotein remnant on platelet aggregation in blood obtained from healthy persons. Thromb. Res. 5: 583-593.
23. Kugiyama, K., H. Doi, T. Motoyama, H. Soejima, K. Misumi, H. Kawano, Y. Ohta, O. Nakagawa, M. Yoshimura, H. Ogawa, T. Matsumura, S. Sugiyama, T. Nakano, K. Nakajima, and H. Yasue. 1998. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation. 97: 2519-2526.
24. Campos, E., K. Nakajima, A. Tanaka, and R. J. Havel. 1992. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. J. Lipid. Res. 33: 369-380.
25. Fredrickson, D. S., J. L. Goldstein, and M. S. Brown. 1978. The familial hyperlipoproteinemias. In The Metabolic Basis of Inherited Diseases. M. F. Stanbury, J. B. Wyngaarden, and D. S. Fredrickson, editors. McGraw-Hill Publishing Co., New York, NY. 604-655.
26. 2-LpE, and α-LpE. J. Lipid Res. 38: 35-48.
27. Warnick, G. R., and J. J. Albers. 1978. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J. Lipid Res. 19: 65-76.
28. Hill, J. S., and P. H. Pritchard. 1990. Improved phenotyping of apolipoprotein E: application to population frequency distribution. Clin. Chem. 36: 1871-1874.
29. Cohn, J. S., M. Tremblay, M. Amiot, D. Bouthillier, M. Roy, J. Genest, Jr., and J. Davignon. 1996. Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects. Arterioscler. Thromb. Vasc. Biol. 16: 149-159.
30. Fredenrich, A., L-M. Giroux, M. Tremblay, L. Krimbou, J. Davignon, and J. S. Cohn. 1997. Plasma lipoprotein distribution of apoC-III in normolipidemic and hyperlipidemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions. J. Lipid Res. 38: 1421-1432.
31. Albers, J. J., M. S. Lodge, and L. K. Curtis. 1989. Evaluation of a monoclonal antibody-based enzyme-linked immunosorbent assay as a candidate reference method for the measurement of apolipoprotein B-100. J. Lipid Res. 30: 1445-1458.
32. Bury, J., and M. Rosseneu. 1985. Quantification of human serum apolipoprotein AI by enzyme immunoassay. Clin. Chem. 31: 247-251.
33. Weisgraber, K. H., T. L. Innerarity, and R. W. Mahley. 1982. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J. Biol. Chem. 257:2518-2521.
34. Kowal, R. C., J. Herz, K. H. Weisgraber, R. W. Mahley, M. S. Brown, and J. L. Goldstein. 1990. Opposing effects of apolipoprotein E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J. Biol. Chem. 265: 10771-10779.
35. Ehnholm, C., R. W. Mahley, D. A. Chappell, K. H. Weisgraber, E. Ludwig, and J. L. Witztum. 1984. Role of apolipoprotein E in the lipolytic conversion of β-very low density lipoproteins to low density lipoproteins in type III hyperlipoproteinemia. Proc. Natl. Acad. Sci. USA. 81: 5566-5570.
36. Gregg, R. E., L. A. Zech, E. J. Schaefer, and H. B. Brewer, Jr. 1981. Type III hyperlipoproteinemia: defective metabolism of an abnormal apolipoprotein E. Science. 211: 584-586.
37. Aalto-Setälä, K., E. A. Fisher, X. Chen, T. Chajek-Shaul, T. Hayek, R. Zechner, A. Walsh, R. Ramakrishnan, H. N. Ginsberg, and J. L. Breslow. 1992. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apoC-III and reduced apoE on the particles. J. Clin. Invest. 90: 1889-1900.
38. de Silva, H. V., S. J. Lauer, J. Wang, W. S. Simonet, K. H. Weisgraber, R. W. Mahley, and J. M. Taylor. 1994. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J. Biol. Chem. 269: 2324-2335.
39. Aalto-Setälä, K., P. H. Weinstock, C. L. Bisgaier, L. Wu, J. D. Smith, and J. L. Breslow. 1996. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse transgenic mice. J. Lipid Res. 37: 1802-1811.
40. Shelburne, F., J. Hanks, W. Meyers, and S. A. Quarfordt. 1980. Effect of apoproteins on hepatic uptake of triglyceride emulsions in the rat. J. Clin. Invest. 65: 652-658.
41. Windler, E., and R. J. Havel. 1985. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J. Lipid Res. 26: 556-563.
42. Brown, V., and M. L. Baginsky. 1972. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochim. Biophys. Acta. 46: 375-382.
43. Krauss, R. M., P. N. Herbert, R. I. Levy, and D. S. Fredrickson. 1973. Further observations on the activation and inhibition of lipoprotein lipase by apolipoproteins. Circ. Res. 33: 403-411.
44. Wang, C-S., W. J. McConathy, H. U. Kloer, and P. Alaupovic. 1985. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J. Clin. Invest. 75: 384-390.
45. Kinnenen, P. K. J., and C. Enholm. 1976. Effect of serum and C-apoproteins from very low density lipoproteins on human post-heparin plasma hepatic lipase. FEBS Lett. 65: 354-357.
46. Pagnan, A., R. J. Havel, J. P. Kane, and L. Kotite. 1977. Characterization of human very low density lipoproteins containing two electrophoretic populations: double pre-beta lipoproteinemia and primary dysbetalipoproteinemia. J. Lipid Res. 18: 613-622.
47. Fielding, C. J., G. R. Castro, C. Donner, P. E. Fielding, and G. M. Reaven. 1986. Distribution of apolipoprotein E in the plasma of insulin-dependent and noninsulin-dependent diabetics and its relation to cholesterol net transport. J. Lipid Res. 27: 1052-1061.
48. Fielding, C. J., J. Frohlich, K. Moser, and P. E. Fielding. 1982. Promotion of sterol efflux and net transport by apolipoprotein E in lecithin:cholesterol acyltransferase deficiency. Metabolism. 31: 1023-1028.
49. Huang, Y., A. von Eckardstein, S. Wu, N. Maeda, and G. Assmann. 1994. A plasma lipoprotein containing only apolipoprotein E and with γ mobility on electrophoresis releases cholesterol from cells. Proc. Natl. Acad. Sci. USA. 91: 1834-1838.
50. Schaefer, E. J., M. G. Wetzel, G. Bengtsson, R. O. Scow, H. B. Brewer, Jr., and T. Olivecrona. 1982. Transfer of human lymph chylomicron constituents to other lipoprotein density fractions during in vitro lipolysis. J. Lipid Res. 23: 1259-1273.
51. Havel, R. I., J. P. Kane, and M. L. Kashyap. 1973. Interchange of apolipoproteins between chylomicrons and high density lipoproteins during alimentary lipemia in man. J. Clin. Invest. 52: 32-38.
52. 2-macroglobulin in human plasma. J. Lipid Res. 39: 2373-2386.